Sign in
4

Changes in Ownership

Enliven Therapeutics, Inc. Filed Acc 0001415889-25-013993

CHIEF SCIENTIFIC OFFICER sold 5,000 shares at $16.31 ($81,534)

  • Traded under a Rule 10b5-1 plan

From the SEC's structured data for this filing

Trades in this filing

Lyssikatos Joseph P · CHIEF SCIENTIFIC OFFICER

Table I: Non-derivative

1 line
Date Transaction Shares Price Value Owned after D/I
2025-05-19 Sale : show line 1 in the form 10b5-1 −5,000 $16.31 $81,534 985,188 I
Open-market sales · 5,000 sh · avg $16.31 · $81,534
Loading xslF345X05/form4-05212025_100540.xml…